Comparing two drugs for adenovirus after stem cell transplant
Part of Infections clinical trials.
This trial tests a new drug, brincidofovir (BCV), against an existing drug, cidofovir (CDV), for treating adenovirus infection in people who recently had a stem cell transplant. The goal is to see which works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant (from someone other than a matched sibling) in the last 6 months.
- You are at least 2 months old.
- You have an active adenovirus infection shown by a blood test (DNA levels at least 1,000 IU/mL, with certain risk factors).
- You have not used the drug cidofovir at high doses in the last 3 weeks.
- You have not received certain cell therapies or vaccines for adenovirus in the last 3 weeks.
- You are not allergic to brincidofovir or cidofovir.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Hear when a new Adenovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.